IMMX
Closed
Immix Biopharma Inc
2.19
+0.12 (+5.80%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 2.07
Day's Range: 2.1 - 2.22
Send
sign up or login to leave a comment!
When Written:
1.85
Immix Biopharma Inc is a clinical-stage biopharmaceutical company that focuses on developing novel cancer immunotherapies. The company's proprietary technology platform, called the Antibody-Coupled T-cell Receptor (ACTR), is designed to enhance the body's immune response to cancer cells.
Immix's lead product candidate, IMX-110, is a first-in-class ACTR therapy that targets CD-19-positive B-cell malignancies, such as non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The company is also developing a pipeline of additional ACTR therapies for various cancer indications.
Immix was founded in 2016 and is headquartered in San Diego, California. The company is publicly traded on the NASDAQ exchange under the ticker symbol IMUX.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Immix's lead product candidate, IMX-110, is a first-in-class ACTR therapy that targets CD-19-positive B-cell malignancies, such as non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The company is also developing a pipeline of additional ACTR therapies for various cancer indications.
Immix was founded in 2016 and is headquartered in San Diego, California. The company is publicly traded on the NASDAQ exchange under the ticker symbol IMUX.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








